Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …

Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

Cardio-oncology has organically developed as a new discipline within cardiovascular
medicine as a result of the cardiac and vascular adverse sequelae of the major advances in …

Human malignancies are often the result of overexpressed and constitutively active receptor
and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor …

Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among
these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the …

Introduction: Sulfonamide compounds are significant class of synthetic bacteriostatic
antibiotics still which used today for the therapy of bacterial infections and those caused by …

Cardiovascular or arteriothrombotic adverse events (CV-or AT-AEs) are reported in chronic
myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). The …

Significance: Antineoplastic therapies have significantly improved the prognosis of oncology
patients. However, these treatments can bring to a higher incidence of side-effects, including …